Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Aeglea BioTherapeutics, Inc. | agle-8k_20170509.htm |
Exhibit 99.1
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
Austin, Texas, May 9, 2017 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2017.
“AEB1102 remains the primary focus of our clinical and preclinical work across rare genetic diseases and cancer,” said David G. Lowe, Ph.D., chief executive officer of Aeglea. “We are especially pleased with recent preclinical data which demonstrated that AEB1102 was not immunosuppressive in combination with anti-PD-1 immune checkpoint inhibitors. We believe this opens a unique opportunity at the intersection of tumor metabolism and existing or emerging therapies in immuno-oncology.”
Recent Highlights
|
|
• |
Presented preclinical data at the 2017 American Association of Cancer Research (AACR) Annual Meeting demonstrating that reducing systemic arginine with AEB1102 did not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerted an additive anti-tumor and synergistic survival benefit. |
|
|
• |
Expanded research and development capabilities with the opening of an internal laboratory at Aeglea in Austin, TX. |
Upcoming Events
|
|
• |
David G. Lowe, Ph.D., chief executive officer of Aeglea, will present a corporate update at the UBS 2017 Global Healthcare Conference being held May 22 – 24, 2017 in New York City. |
First Quarter 2017 Financial Results
At March 31, 2017, Aeglea had available cash, cash equivalents and marketable securities of $57.9 million. Based on Aeglea’s current operating plan, management believes that it has sufficient capital resources to fund anticipated operations through March 31, 2019.
Aeglea recognized grant revenues of $1.0 million in the first quarter of 2017, compared with $0.9 million in the first quarter of 2016. The grant revenues are the result of a $19.8 million research grant received from the Cancer Prevention and Research Institute of Texas (CPRIT). The increase was primarily due to higher qualifying expenditures associated with AEB1102 for grant-related clinical trials.
Research and development expenses totaled $4.9 million for the first quarter of 2017, compared with $3.6 million for the first quarter of 2016. The increase was primarily associated with hiring additional personnel to expand Aeglea’s internal regulatory, laboratory, and clinical development capabilities.
General and administrative expenses totaled $2.3 million for the first quarter of 2017, compared to $1.8 million in the first quarter of 2016. This increase was primarily due to additional compensation and personnel costs, and increased costs associated with operating as a public company.
Net loss totaled $6.2 million and $4.5 million for the first quarter of 2017 and 2016, respectively.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase 1 Deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar
references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Kelly Boothe, Ph.D.
Pure Communications
415.946.1076
media@aegleabio.com
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|
|
|
March 31, |
|
|
December 31, |
|
||
|
|
|
2017 |
|
|
2016 |
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
16,801 |
|
|
$ |
47,748 |
|
|
Marketable securities |
|
|
41,067 |
|
|
|
15,754 |
|
|
Accounts receivable - grant |
|
|
981 |
|
|
|
1,215 |
|
|
Prepaid expenses and other current assets |
|
|
1,456 |
|
|
|
1,707 |
|
|
Total current assets |
|
|
60,305 |
|
|
|
66,424 |
|
|
Property and equipment, net |
|
|
822 |
|
|
|
599 |
|
|
Other non-current assets |
|
|
140 |
|
|
|
40 |
|
|
TOTAL ASSETS |
|
$ |
61,267 |
|
|
$ |
67,063 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
267 |
|
|
$ |
168 |
|
|
Deferred revenue |
|
|
51 |
|
|
|
71 |
|
|
Accrued and other current liabilities |
|
|
3,639 |
|
|
|
3,726 |
|
|
Total current liabilities |
|
|
3,957 |
|
|
|
3,965 |
|
|
Other non-current liabilities |
|
|
127 |
|
|
|
132 |
|
|
TOTAL LIABILITIES |
|
|
4,084 |
|
|
|
4,097 |
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2017 and December 31, 2016; no shares issued and outstanding as of March 31, 2017 and December 31, 2016 |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2017 and December 31, 2016; 13,452,260 shares and 13,430,833 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively |
|
|
1 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
|
108,743 |
|
|
|
108,246 |
|
|
Accumulated other comprehensive loss |
|
|
(37 |
) |
|
|
(4 |
) |
|
Accumulated deficit |
|
|
(51,524 |
) |
|
|
(45,277 |
) |
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
57,183 |
|
|
|
62,966 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
61,267 |
|
|
$ |
67,063 |
|
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
|
2017 |
|
|
2016 |
|
||
|
Revenues: |
|
|
|
|
|
|
|
|
|
Grant |
|
$ |
982 |
|
|
$ |
859 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
4,949 |
|
|
|
3,596 |
|
|
General and administrative |
|
|
2,364 |
|
|
|
1,830 |
|
|
Total operating expenses |
|
|
7,313 |
|
|
|
5,426 |
|
|
Loss from operations |
|
|
(6,331 |
) |
|
|
(4,567 |
) |
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
Interest income |
|
|
95 |
|
|
|
26 |
|
|
Other expense, net |
|
|
(11 |
) |
|
|
(6 |
) |
|
Total other income |
|
|
84 |
|
|
|
20 |
|
|
Net loss |
|
$ |
(6,247 |
) |
|
$ |
(4,547 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(0.47 |
) |
|
$ |
(7.10 |
) |
|
Weighted-average common shares outstanding, basic and diluted |
|
|
13,365,823 |
|
|
|
640,699 |
|